Judge approves $7.25bn Roundup settlement

A judge in Missouri has approved Bayer’s $7.25 billion settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could finally resolve litigation that has weighed on the German company for a decade.
St. Louis Circuit Judge Timothy Boyer granted final approval on Friday to the nationwide class settlement, finding it “fair, reasonable and adequate”. The settlement covers people who were exposed to Roundup before 17 February 2026 and developed non-Hodgkin lymphoma, a form of cancer, as well as people diagnosed in future.
Individual payouts will range from $10,000 to $165,000, depending on how the product was used, the age at diagnosis and the severity of the illness. The settlement also includes $600 million for lawyers’ fees. The judge described the total as among the largest in the history of mass tort personal-injury class action settlements.
Payments spread over 21 years
Monsanto, the Bayer subsidiary that makes Roundup, will make declining capped annual payments into a fund for up to 21 years, totalling as much as $7.25 billion, including payments already made.
The settlement has two groups of claimants: people who already have a diagnosis of non-Hodgkin lymphoma, and people who receive a diagnosis during a 16-year period after the settlement is finally approved. Claims can be brought regardless of the legal theory behind them.
Bayer denies that Roundup causes cancer, and has said the settlement gives it financial certainty after years of mounting legal costs that had led it to consider withdrawing the product from United States farm markets. Its chief executive, Bill Anderson, called the court’s approval “a decisive milestone” in the company’s plan to contain the litigation.
Supreme Court ruling cleared the way
The settlement follows a United States Supreme Court ruling in June in a case known as Durnell, in which the court held 7-2 that federal pesticide law prevents states from requiring cancer warnings on Roundup that the federal regulator has not required. Judge Boyer cited that ruling when he found the settlement met the test for adequacy.
The decision also followed a unanimous defence verdict in a case known as Aretino, the first to go to trial since the Supreme Court’s ruling.
Judge Boyer said there was a risk that Bayer would have sought bankruptcy protection if the settlement had been rejected. The court’s approval order can be appealed.
Bayer bought Monsanto for $63 billion in 2018, inheriting the Roundup litigation. The settlement is designed to resolve both present and future claims through a long-term claims programme, rather than through individual trials.